SUMMARY
Andy Abril, M.D., studies clinical appearances, diagnostic methods and new treatments for systemic sclerosis. These treatments include cellular therapies, new medicines and autologous stem cell bone marrow transplant. He researches interstitial lung disease associated with connective tissue problems including systemic sclerosis.
Dr. Abril also has years of experience in the diagnosis and treatment of systemic vasculitis. He participated in the creation of diagnostic and treatment guidelines for systemic vasculitis both nationally and internationally.
Focus areas
Systemic sclerosis. Dr. Abril participates in clinical trials of new therapies including new medications and cellular therapy such as chimeric antigen receptor (CAR)-T cell therapy.
Dr. Abril studies clinical outcomes of people with systemic sclerosis treated with autologous stem cell bone marrow transplants.
Dr. Abril takes part in diagnostic studies for systemic sclerosis and other connective tissue disorders, such as using video capillaroscopy.
Systemic vasculitis. Dr. Abril is a member of the American College of Rheumatology team drafting and updating the diagnostic and treatment criteria for systemic vasculitis.
Dr. Abril studies the pulmonary appearances of different types of systemic vasculitides.
Significance to patient care
New therapies for systemic sclerosis are much needed since this is a progressive multisystemic disorder that traditionally has not responded well to medicines. New therapies such as autologous stem cell transplant are promising for many people with systemic sclerosis. Established treatment for individuals with systemic sclerosis has opened the door for cellular therapies such as CAR-T cell therapy and new, more-targeted pharmacological therapies.
Now, there are more treatment alternatives for people with systemic sclerosis. Dr. Abril studies clinical outcomes of individuals with systemic sclerosis treated with autologous stem cell bone marrow transplant and takes part in clinical trials of cellular therapies and new medicines.